Öffentliche Vorlesung im Rahmen des Weiterbildungsprogramms „Translationale Forschung & Medizin: Von der Idee zum Produkt“ der TRAIN-Akademie:
Sprecher: Dr. Cord Dohrmann, CSO Evotec AG
"Forging high-value collaborations between academia, biotech and big pharma – the Evotec approach"
Wann: Donnerstag, 02.03.2017, 16:30 Uhr
Wo: CRC Hannover | Feodor-Lynen-Straße 15 | Raum H0.072
Vita
Dr Cord Dohrmann joined Evotec AG as Chief Scientific Officer and Member of the Management Board on 01 September 2010. Dr Dohrmann has spent over 20 years in biomedical research at leading academic institutions and in the biotech industry. He started his academic career in 1983 studying Biology at Tübingen University in Germany and conducting research as a DAAD scholar at Duke University, Durham, USA. Dr. Dohrmann completed his MA thesis at the Max-Planck Institute in Tübingen and subsequently enrolled at the Harvard Medical School in Boston, USA, where he received his Ph.D. in Cell and Developmental Biology in 1996.
Dr. Dohrmann continued his career as a Shiseido research fellow at the Massachusetts General Hospital in Boston before joining DeveloGen in 1999. He served the company in various management positions including CEO, leading DeveloGen from a start-up to an internationally recognised metabolic disease company with a pipeline of highly innovative preclinical and clinical products for the treatment of diabetes and related disorders. Dr. Dohrmann has been advising the European Commission, the Max-Planck-Institute as well as venture capital firms and authored and co-authored a number of publications and patents.
Abstract
Evotec positions itself as globally leading biotechnology company that leverages its established drug discovery alliance business into high-value collaborative models between academia, non-for-profit organization, biotech and pharma. In part this is driven through the Cure X and Target X initiatives within selected indication areas of both high unmet medical need and perceived lack of innovation. The purpose of these is to prime biotech/pharma licensing and collaboration. In doing so Evotec maintains a portfolio of clinical stage assets de-risked through partnering. More recently also Evotec started to co-invest into start-up companies. In my presentation I will highlight our systematic approach at finding academic projects, accelerating these through industrialized drug discovery and partnering these to clinical-stage developers.